Thrombosis News and Research

Latest Thrombosis News and Research

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Safety of birth control pills under scrutiny

Bayer’s oral contraceptive pills are being reviewed by regulators after some studies suggested they may cause more blood clots than competing medicines.

5 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

Omega-3 fatty acids reduce risk of heart attack in stent patients

Omega-3 fatty acids, combined with two blood-thinning drugs, significantly changed the blood-clotting process and may reduce the risk of heart attacks in patients with stents in their heart arteries, according to research reported in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.

27 May 2011

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.

From Medtronic 21 May 2011

Blood stored in banks may undergo changes and damage

New research provides evidence for significant differences between new and old red blood cells used for transfusions and could provide a cheap, rapid and effective way to monitor the quality of blood supplies.

21 May 2011

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the DRug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device.

19 May 2011

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.

From Medtronic 18 May 2011

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society in the journal Maturitas on managing menopausal women with a personal or family history of venous thromboembolism.

18 May 2011

Accumetrics' VerifyNow P2Y12 Test receives CE mark approval for prognostic use

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity on antiplatelet therapy who are at greater risk for future cardiovascular events.

17 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Doctors miss blood clots costing millions to the NHS: Report

According to to figures from the NHS Litigation Authority, the NHS has paid out over £112m since 2005 in compensation because doctors have failed to spot or prevent fatal blood clots.

12 May 2011

Medtronic to present new clinical results on innovative medical devices at EuroPCR

New clinical data on a range of innovative medical devices from Medtronic, Inc., to treat cardiac and vascular diseases - from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease - will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17-20.

From Medtronic 12 May 2011

Thrombosis News and Research

Latest Thrombosis News and Research

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Safety of birth control pills under scrutiny

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Birth control pill safety issues raised

Omega-3 fatty acids reduce risk of heart attack in stent patients

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Blood stored in banks may undergo changes and damage

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Accumetrics' VerifyNow P2Y12 Test receives CE mark approval for prognostic use

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Doctors miss blood clots costing millions to the NHS: Report

Medtronic to present new clinical results on innovative medical devices at EuroPCR

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Thrombosis News and Research

Latest Thrombosis News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in